Literature DB >> 18395192

Central projections of the sensory innervation of the rat middle meningeal artery.

Yi Liu1, Jonas Broman, Lars Edvinsson.   

Abstract

Headaches, especially migraine, involve not only pain but also aspects such as vasodilation of cranial vessels and sensitization of nerve endings, processes dependent on and connected to the central nervous system. To understand pathogenic mechanisms of headache, it is important to elucidate the central projections of sensory nerves that innervate cranial vessels, of which the middle meningeal artery (MMA) is the largest artery supplying the dura mater. In this study, cholera toxin subunit b (CTb) or wheat germ agglutinin-horseradish peroxidase conjugate (WGA-HRP) was applied on the adventitia of MMA. After perfusion fixation, the brainstem, the C1-C4 spinal segments and the trigeminal and C2 dorsal root ganglia were removed and sections from these tissues were processed to visualize transported tracers. Labeled cell bodies were seen ipsilaterally in the trigeminal and C2 dorsal root ganglia. Labeled nerve terminations were found ipsilaterally in the lateral part of the spinal dorsal horn of segments C1-C3 and in the caudal and interpolar parts of the spinal trigeminal nucleus. WGA-HRP labeled terminations were mainly located in laminae I and II, whereas CTb labeled terminations located in laminae III-V. These results indicate that sensory information from the MMA is transmitted through both trigeminal and cervical spinal nerve branches to a region in the central nervous system extending rostrally from the C3 dorsal horn to the interpolar part of the spinal trigeminal nucleus. Our data further substantiates that the sensory innervation of the MMA, in addition to putative nociceptive afferents, include a population of large caliber afferents with an as yet unclear but presumably non-nociceptive role.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395192     DOI: 10.1016/j.brainres.2008.02.078

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  22 in total

Review 1.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

2.  Trigeminal Pain Molecules, Allodynia, and Photosensitivity Are Pharmacologically and Genetically Modulated in a Model of Traumatic Brain Injury.

Authors:  Brittany V Daiutolo; Ashley Tyburski; Shannon W Clark; Melanie B Elliott
Journal:  J Neurotrauma       Date:  2015-12-17       Impact factor: 5.269

Review 3.  CGRP receptor antagonism and migraine.

Authors:  Lars Edvinsson; Tony W Ho
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

Review 4.  An update on the blood vessel in migraine.

Authors:  K C Brennan; Andrew Charles
Journal:  Curr Opin Neurol       Date:  2010-06       Impact factor: 5.710

Review 5.  Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation.

Authors:  Ann C Raddant; Andrew F Russo
Journal:  Expert Rev Mol Med       Date:  2011-11-29       Impact factor: 5.600

6.  CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

Authors:  Lars Edvinsson
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

Review 7.  CGRP and migraine: could PACAP play a role too?

Authors:  Eric A Kaiser; Andrew F Russo
Journal:  Neuropeptides       Date:  2013-10-23       Impact factor: 3.286

Review 8.  Migraine in the era of precision medicine.

Authors:  Lv-Ming Zhang; Zhao Dong; Sheng-Yuan Yu
Journal:  Ann Transl Med       Date:  2016-03

9.  Sensory innervation of the calvarial bones of the mouse.

Authors:  Bela Kosaras; Moshe Jakubowski; Vanessa Kainz; Rami Burstein
Journal:  J Comp Neurol       Date:  2009-07-20       Impact factor: 3.215

10.  Migraine: Telcagepant provides new hope for people with migraine.

Authors:  Lars Edvinsson
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.